Alternative lengthening of telomeres: mechanism and the pathogenesis of cancer

Highlighting vulnerabilities in the alternative lengthening of telomeres pathway

(2023) Lisa M. Carson et al.   CURRENT OPINION IN PHARMACOLOGY

Signalling inhibition by ponatinib disrupts productive alternative lengthening of telomeres (ALT)

(2023) Frances Karla Kusuma et al.   Nature Communications

Predicting recurrence in pancreatic neuroendocrine tumours: role of ARX and alternative lengthening of telomeres (ALT)

(2023) Azfar Neyaz et al.   HISTOPATHOLOGY

Hallmarks of Cancer: New Dimensions

(2022) Douglas Hanahan   Cancer Discovery

Classification of adult‐type diffuse gliomas: Impact of the World Health Organization 2021 update

(2022) Benjamin T. Whitfield et al.   BRAIN PATHOLOGY

Telomeric replication stress: the beginning and the end for alternative lengthening of telomeres cancers

(2022) Robert Lu et al.   Open Biology

The Diagnostic and Prognostic Utility of Incorporating DAXX, ATRX, and Alternative Lengthening of Telomeres (ALT) to the Evaluation of Pancreatic Neuroendocrine Tumors (PanNETs)

(2022) Christopher M. Heaphy et al.   HUMAN PATHOLOGY

Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteome

(2021) Sabine A. Hartlieb et al.   Nature Communications

Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size

(2021) Wenzel M Hackeng et al.   GUT

ALT Positivity in Human Cancers: Prevalence and Clinical Insights

(2021) Danny MacKenzie et al.   Cancers

Clinicopathological and molecular characterization of chromophobe hepatocellular carcinoma

(2021) Hyo Jeong Kang et al.   LIVER INTERNATIONAL

Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice?

(2021) Claudio Luchini et al.   Current Oncology Reports

Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system

(2021) Simon Gritsch et al.   CANCER

Alternative Lengthening of Telomeres: Lessons to Be Learned from Telomeric DNA Double-Strand Break Repair

(2021) Thomas Kent et al.   Genes

The C-Circle Biomarker Is Secreted by Alternative-Lengthening-of-Telomeres Positive Cancer Cells inside Exosomes and Provides a Blood-Based Diagnostic for ALT Activity

(2021) Yuan-Yin Chen et al.   Cancers

Centromeric cohesion failure invokes a conserved choreography of chromosomal mis-segregations in pancreatic neuroendocrine tumor

(2020) Rene Quevedo et al.   Genome Medicine

Alternative Lengthening of Telomeres through Two Distinct Break-Induced Replication Pathways

(2019) Jia-Min Zhang et al.   Cell Reports

RAD52 and SLX4 act nonepistatically to ensure telomere stability during alternative telomere lengthening

(2019) Priyanka Verma et al.   GENES & DEVELOPMENT

Alternative lengthening of telomeres (ALT) influences survival in soft tissue sarcomas: a systematic review with meta-analysis

(2019) Rita T. Lawlor et al.   BMC CANCER

The FANCM-BLM-TOP3A-RMI complex suppresses alternative lengthening of telomeres (ALT)

(2019) Robert Lu et al.   Nature Communications

FANCM limits ALT activity by restricting telomeric replication stress induced by deregulated BLM and R-loops

(2019) Bruno Silva et al.   Nature Communications

Author Correction: Rad52 prevents excessive replication fork reversal and protects from nascent strand degradation

(2019) Eva Malacaria et al.   Nature Communications

SLX4IP Antagonizes Promiscuous BLM Activity during ALT Maintenance

(2019) Stephanie Panier et al.   MOLECULAR CELL

The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma

(2018) Bill H. Diplas et al.   Nature Communications

The C-Circle Assay for alternative-lengthening-of-telomeres activity

(2017) Jeremy D. Henson et al.   METHODS

Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival

(2016) Joo Young Kim et al.   CLINICAL CANCER RESEARCH

Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors

(2016) Aatur D. Singhi et al.   CLINICAL CANCER RESEARCH

Alternative lengthening of human telomeres is a conservative DNA replication process with features of break‐induced replication

(2016) Fani‐Marlen Roumelioti et al.   EMBO REPORTS

Break-induced telomere synthesis underlies alternative telomere maintenance

(2016) Robert L. Dilley et al.   NATURE

SMARCAL1 Resolves Replication Stress at ALT Telomeres

(2016) Kelli E. Cox et al.   Cell Reports

Exome Sequencing of Uterine Leiomyosarcomas Identifies Frequent Mutations in TP53, ATRX, and MED12

(2016) Netta Mäkinen et al.   PLoS Genetics

Roles of human POLD1 and POLD3 in genome stability

(2016) Emanuela Tumini et al.   Scientific Reports

Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors

(2015) R. L. Flynn et al.   SCIENCE

Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma

(2015) Kasthuri Kannan et al.   Oncotarget

Loss of DAXX and ATRX Are Associated With Chromosome Instability and Reduced Survival of Patients With Pancreatic Neuroendocrine Tumors

(2013) Ilaria Marinoni et al.   GASTROENTEROLOGY

Chromophobe hepatocellular carcinoma with abrupt anaplasia: a proposal for a new subtype of hepatocellular carcinoma with unique morphological and molecular features

(2013) Laura D Wood et al.   MODERN PATHOLOGY

Causes and consequences of replication stress

(2013) Michelle K. Zeman et al.   NATURE CELL BIOLOGY

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

(2013) P. J. Killela et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Loss of ATRX, Genome Instability, and an Altered DNA Damage Response Are Hallmarks of the Alternative Lengthening of Telomeres Pathway

(2012) Courtney A. Lovejoy et al.   PLoS Genetics

Prevalence of the Alternative Lengthening of Telomeres Telomere Maintenance Mechanism in Human Cancer Subtypes

(2011) Christopher M. Heaphy et al.   AMERICAN JOURNAL OF PATHOLOGY

Altered Telomeres in Tumors with ATRX and DAXX Mutations

(2011) C. M. Heaphy et al.   SCIENCE